AMPIO PHARMACEUTICALS, INC. (NYSEAMERICAN: AMPE) Files An 8-K Entry into a Material Definitive Agreement

AMPIO PHARMACEUTICALS, INC. (NYSEAMERICAN: AMPE) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

Story continues below

As previously reported, on August 9, 2018, Ampio Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement, as amended by Amendment No. 1 thereto dated August 10, 2018, with Canaccord Genuity LLC as the sole underwriter, to which the Company issued, among other things, warrants (the “Warrants”) to purchase up to 20,000,000 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), with an exercise price of $0.40 per share.

On December 7, 2018, the Company entered into a Warrant Exercise Agreement (the “Exercise Agreement”) with a certain holder of the Warrants (the “Exercising Holders”), which Exercising Holder owns Warrants exercisable for 3,450,000 shares of Common Stock. to the Exercise Agreement, the Exercising Holder and the Company agreed that the Exercising Holder would exercise their Warrants with respect to 1,725,000 shares of Common Stock underlying such Warrants for a reduced exercise price equal to $0.30 per share.

The Company expects to receive aggregate gross proceeds of approximately $517,500 from the exercise of the Warrants by the Exercising Holder. In addition, the exercise will result in the reduction of warrants to purchase Common Stock of the Company by approximately 7% and is not dilutive to existing security holders of the Company calculated on a fully diluted basis for outstanding warrants.

The description of the Exercise Agreement set forth herein does not purport to be complete and is qualified in its entirety by reference to the full text of the form of Exercise Agreement attached hereto as Exhibit 10.1.

Item 3.03 Material Modification to Rights of Security Holders.

The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.03.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number Description
10.1 Form of Warrant Exercise Agreement

Ampio Pharmaceuticals, Inc. Exhibit
EX-10.1 2 tv508716_ex10-1.htm EXHIBIT 10.1   Exhibit 10.1     WARRANT EXERCISE AGREEMENT   This Warrant Exercise Agreement (this “Agreement”),…
To view the full exhibit click here

An ad to help with our costs